Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Introgen Therapeutics receives milestone payment from RPR

July 1, 1999

Aronex reports responses in phase II trial of Atragen as treatment of NHL

June 30, 1999

New compounds from Merck inhibit posttranslational farnesylation of proteins

June 30, 1999

FeRx's targeted carrier tested in doxorubicin delivery to liver cancer patients

June 30, 1999

QLT terminates collaboration with Beaufour Ipsen

June 30, 1999

Continued focus at Merck on inhibitors of protein farnesyltransferase

June 29, 1999

Ligand submits NDA for Targretin capsules and reports positive interim data from psoriasis study

June 29, 1999

Magainin begins phase II testing of squalamine

June 29, 1999

Ethyol approved by FDA for radiation-induced dry mouth

June 28, 1999

Et-743, a potent anticancer agent with a complex, unique mechanism of action

June 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.